Clinical Trial Update: GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating GDC-0449 (vismodegib) and erlotinib hydrochloride, with or without gemcitabine hydrochloride, in metastatic pancreatic cancer or inoper…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Acinar Cell Carcinoma
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Erlotinib hydrochloride (Tarceva) (erlotinib)
• GDC-0449 (vismodegib) (vismodegib)
• Gemcitabine hydrochloride (Gemzar) (gemcitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING